Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative putrilimab plus 维贝柯妥塔单抗 in resectable locally advanced head and neck squamous cell carcinoma
CTR20261692Phase 2Active
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of putrilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Lepu Biopharma Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
putrilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20261692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261692.